M. Jones

Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT

Napp, D. Altman, C. Sturgeon, 2018, Programme Grants for Applied Research.

Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.

D. Matei, I. Vergote, S. Kaye, 2009, European journal of cancer.

Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.

R. Eeles, Z. Kote-Jarai, M. Guy, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study.

M. Jones, D. Wallace, K. Kelly, 1989, Progress in clinical and biological research.

Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC).

I. Vergote, M. Jones, P. Rose, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial comparing zoladex 3.6 mg depot with stilboestrol 3mg/day in advanced prostate cancer: Patient characteristics, response and treatment failures

D. Farrar, M. Jones, D. Wallace, 1987 .

Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.

J. Kolesar, M. Jones, T. Campbell, 2011, Journal of Clinical Oncology.